Gain insights from our experts...
Optimizing lipid nanoparticles (LNPs) processing for siRNA delivery by microfluidics system
The success of mRNA vaccines during the COVID-19 pandemic has accelerated the advancement of nucleic acid delivery technologies. In addition to mRNA, interfering RNA offers potential to treat diseases beyond the reach of small molecules. However, therapeutic success hinges on efficient and targeted delivery systems. Lipid nanoparticles (LNPs), especially those produced via microfluidics, have emerged as a leading platform for RNA delivery. delivery. for RNA.
Join Dr. Qiaobin Hu as he explores LNP formulation for siRNA delivery using a microfluidic flow-focusing system.
Optimising lipid nanoparticles (LNPs) processing for siRNA delivery by microfluidics system
866.3 KB
Explore our poster presentation with Qiaobin Hu
Explore additional content
Explore recent blogs:
Replacing Triton™ X‑100 Without Compromise: Meet Virodex™
If you were at BioProcess International Europe this year, you may have caught a glimpse of us talking about detergent alternatives for viral inactivation. If you weren’t, or if you’ve since heard the...
Bioprocessing spotlight: Meet the Croda Pharma experts heading to BioProcess International Europe
As BioProcess International Europe in Vienna approaches this Spring, we’re excited to take part in the conversations around technologies, trends and meet the people translating science into progress.
BioXPro™ high purity amino acids now available
Croda successfully launches new Amino Acid range BioXPro™: Croda International Plc (“Croda”) today confirms the successful introduction of its latest portfolio of high purity amino acids, developed to...